Dr Anurag Agarwal, member of the WHO’s Technical Advisory Group on Sars-CoV-2 Virus Evolution, explains if another round of vaccination makes sense or not.
Drug manufacturers will make available 230,000 additional doses of the respiratory syncytial virus (RSV) shot for infants by mid-January for this RSV season, amid a nationwide shortage that’s left parents and pediatricians scrambling. White House officials have been privately meeting with drug manufacturers and partners of RSV immunizations almost weekly, including Sanofi, AstraZeneca and Thermo…
Additional doses for the prophylaxis of respiratory syncytial virus will immediately be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program.
The Centers for Disease Control and Prevention said it was releasing 77,000 additional doses of a respiratory syncytial virus (RSV) drug from Sanofi and AstraZeneca to help improve its availability. The additional doses of Beyfortus will be distributed immediately to physicians and hospitals through the Vaccines for Children Program, which covers the cost of the…